Bisphosphonates in osteoporosis
- 1 October 2003
- journal article
- review article
- Published by Springer Nature in European Spine Journal
- Vol. 12 (2) , S142-S146
- https://doi.org/10.1007/s00586-003-0622-z
Abstract
Bisphosphonates are compounds characterized by a P-C-P structure. They act essentially on bone, inhibiting bone resorption. Through this mechanism they decrease bone loss, increase bone mineral density, and decrease bone turnover. They are therefore administered in diseases with elevated bone destruction, such as Paget's disease, metastatic bone disease, and osteoporosis. In the latter they diminish both vertebral and nonvertebral fractures. The adverse events are few, mostly gastrointestinal, and can be avoided to a large extent by correct administration. Since there are no other compounds available which have a similar profile, they represent today the drugs of choice in the treatment and the secondary prevention of osteoporosis.Keywords
This publication has 19 references indexed in Scilit:
- New Insights Into the Molecular Mechanisms of Action of BisphosphonatesCurrent Pharmaceutical Design, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with OsteoporosisNew England Journal of Medicine, 2001
- Skeletal Benefits of Alendronate: 7-Year Treatment of Postmenopausal Osteoporotic Women1Journal of Clinical Endocrinology & Metabolism, 2000
- Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal OsteoporosisOsteoporosis International, 2000
- Risedronate therapy prevents corticosteroid-induced bone loss : A twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyArthritis & Rheumatism, 1999
- Multinational, Placebo-Controlled, Randomized Trial of the Effects of Alendronate on Bone Density and Fracture Risk in Postmenopausal Women with Low Bone Mass: Results of the FOSIT StudyOsteoporosis International, 1999
- Intermittent Cyclical Etidronate Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 1990
- Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl2MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of ratsCalcified Tissue International, 1973
- Diphosphonates Inhibit Formation of Calcium Phosphate Crystals in vitro and Pathological Calcification in vivoScience, 1969